Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 41.4%
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 41.4%
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Rating) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 18,400 shares, a drop of 41.4% from the October 15th total of 31,400 shares. Based on an average daily trading volume, of 103,900 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.
喜力治療公司(納斯達克代碼:XLO-GET評級)是空頭股數10月份大幅下跌的目標。截至10月31日,空頭股數共有1.84萬股,較10月15日的3.14萬股減少了41.4%。以日均成交量103,900股計算,目前天數與回補比率為0.2天。目前,該公司0.2%的股票被賣空。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several equities research analysts have recently weighed in on the company. Morgan Stanley cut their target price on Xilio Therapeutics from $32.00 to $20.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 10th. Raymond James cut their target price on Xilio Therapeutics from $31.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Xilio Therapeutics has a consensus rating of "Buy" and an average price target of $16.50.
幾位股票研究分析師最近對該公司進行了分析。8月10日,週三,摩根士丹利在一份研究報告中將喜力治療的目標價從32.00美元下調至20.00美元,並對該股設定了“增持”評級。Raymond James在週四的一份研究報告中將Xilio治療公司的目標價從31.00美元下調至13.00美元,並對該股設定了“跑贏大盤”的評級。根據MarketBeat的數據,五位投資分析師對該股的評級為買入,希利奧治療公司的共識評級為“買入”,平均目標價為16.50美元。
Institutional Inflows and Outflows
機構資金流入和流出
Several institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP acquired a new position in Xilio Therapeutics during the second quarter worth approximately $417,000. State Street Corp grew its stake in shares of Xilio Therapeutics by 58.5% in the 1st quarter. State Street Corp now owns 93,861 shares of the company's stock valued at $664,000 after purchasing an additional 34,651 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $220,000. Millennium Management LLC purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $146,000. Finally, Bailard Inc. purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $107,000. Institutional investors and hedge funds own 64.66% of the company's stock.
幾家機構投資者最近增持或減持了該公司的股份。Laurion Capital Management LP在第二季度收購了Xilio治療公司的一個新頭寸,價值約41.7萬美元。道富集團在第一季度增持了Xilio Treeutics的股份58.5%。道富銀行目前持有93,861股該公司股票,價值664,000美元,此前該公司在上個季度又購買了34,651股。復興技術有限責任公司在第二季度購買了西利奧治療公司的新股票,價值約22萬美元。千禧管理公司在第二季度購買了西利奧治療公司的新股票,價值約為146,000美元。最後,Bailard Inc.在第二季度購買了價值約10.7萬美元的希利奧治療公司的新頭寸。機構投資者和對衝基金持有該公司64.66%的股票。
Xilio Therapeutics Stock Performance
喜力治療的股票表現
Xilio Therapeutics (NASDAQ:XLO – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.12). Equities research analysts forecast that Xilio Therapeutics will post -3.49 EPS for the current year.
喜力治療(納斯達克:XLO-GET評級)最近一次發佈季度收益報告是在8月9日(星期二)。該公司公佈本季度每股收益(0.90美元),低於(0.78美元)和(0.12美元)的普遍預期。股票研究分析師預測,希利奧治療公司本年度每股收益將達到3.49歐元。
Xilio Therapeutics Company Profile
西利奧治療公司簡介
(Get Rating)
(獲取評級)
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
Xilio Treateutics,Inc.是一家臨牀階段的生物技術公司,開發免疫療法來改善癌症患者的免疫系統。其檢查點抑制計劃包括XTX101,這是一種臨牀分期、腫瘤選擇性的抗CTLA-4單抗,正處於實體瘤患者的1/2期臨牀試驗中。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免費獲取StockNews.com關於希利奧治療公司(XLO)的研究報告
- MarketBeat:回顧中的一週11/7-11/11
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎?
- 六面旗幟是一種你不想被困住的旅程
- Hanesbrand可能發出零售類股本週表現不佳的信號
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《喜力治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Xilio Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。